Cho, Oyeon; Noh, O Kyu; Oh, Young-Taek; Chang, Suk-Joon; Chun, Mison
Anticancer research
2017Jan ; 37 ( 1 ) :327-334.
PMID : 28011510
ÀúÀÚ »ó¼¼Á¤º¸
Cho, Oyeon -
Noh, O Kyu -
Oh, Young-Taek -
Chang, Suk-Joon -
Chun, Mison -
ABSTRACT
BACKGROUND/AIM: To investigate whether high-dose-rate (HDR) intracavitary brachytherapy (IBT) dose ratios can predict treatment outcomes in patients with stage IIB cervical cancer. PATIENTS AND
METHODS: Ninety-three patients treated with weekly cisplatin-based concurrent chemoradiotherapy and HDR IBT were analyzed. Potential prognostic factors and treatment outcomes were compared between low-HDR-IBT-ratio (??.43) and high-HDR-IBT-ratio (>0.43) groups, and univariate and multivariate analyses were performed.
RESULTS: Five-year disease-specific survival (DSS) and progression-free survival (PFS) rates were significantly shorter in the low-compared to the high-HDR-IBT-ratio group. A high HDR IBT ratio was confirmed as an independent prognostic factor for DSS and PFS. CONCLUSION: A high HDR IBT dose ratio improves DSS and PFS in patients with stage IIB cervical cancer. Therefore, active administration of HDR IBT beyond previously accepted levels may be necessary for the treatment of locally advanced cervical cancer. CI - Copyright??2017 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
Cervical cancer; high-dose-rate intracavitary brachytherapy; survival
MESH
Aged, Antineoplastic Agents/*therapeutic use, *Brachytherapy, *Chemoradiotherapy, Cisplatin/*therapeutic use, Disease-Free Survival, Female, Humans, Neoplasm Staging, Radiotherapy Dosage, Treatment Outcome, Uterine Cervical Neoplasms/pathology/*therapy
¸µÅ©